Diadema Partners LP Takes Position in Arcus Biosciences, Inc. (NYSE:RCUS)

Diadema Partners LP purchased a new position in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 165,965 shares of the company's stock, valued at approximately $2,471,000. Arcus Biosciences comprises about 1.0% of Diadema Partners LP's portfolio, making the stock its 20th biggest position. Diadema Partners LP owned 0.18% of Arcus Biosciences at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in RCUS. MetLife Investment Management LLC boosted its position in Arcus Biosciences by 8.1% during the fourth quarter. MetLife Investment Management LLC now owns 33,525 shares of the company's stock valued at $499,000 after purchasing an additional 2,521 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Arcus Biosciences by 11.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,702,302 shares of the company's stock valued at $25,348,000 after buying an additional 178,351 shares in the last quarter. First Trust Advisors LP increased its holdings in Arcus Biosciences by 43.1% during the fourth quarter. First Trust Advisors LP now owns 17,708 shares of the company's stock worth $264,000 after buying an additional 5,337 shares during the last quarter. Gilead Sciences Inc. bought a new stake in Arcus Biosciences during the fourth quarter worth $447,610,000. Finally, PEAK6 LLC acquired a new stake in Arcus Biosciences in the fourth quarter valued at $149,000. 92.89% of the stock is owned by institutional investors.

Insider Transactions at Arcus Biosciences

In other Arcus Biosciences news, CEO Terry J. Rosen acquired 19,800 shares of the company's stock in a transaction that occurred on Thursday, February 27th. The stock was acquired at an average price of $10.18 per share, for a total transaction of $201,564.00. Following the acquisition, the chief executive officer now directly owns 2,554,160 shares in the company, valued at $26,001,348.80. This represents a 0.78 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Yasunori Kaneko bought 20,000 shares of Arcus Biosciences stock in a transaction on Thursday, February 27th. The shares were acquired at an average cost of $10.06 per share, for a total transaction of $201,200.00. Following the completion of the acquisition, the director now directly owns 28,400 shares in the company, valued at approximately $285,704. The trade was a 238.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 12.30% of the company's stock.

Arcus Biosciences Price Performance

Shares of RCUS traded down $0.11 during midday trading on Friday, hitting $8.30. The company's stock had a trading volume of 503,744 shares, compared to its average volume of 801,683. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08. Arcus Biosciences, Inc. has a one year low of $6.50 and a one year high of $18.98. The stock has a market capitalization of $872.65 million, a price-to-earnings ratio of -2.63 and a beta of 1.54. The company's fifty day simple moving average is $8.79 and its two-hundred day simple moving average is $13.03.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($1.03) EPS for the quarter, topping the consensus estimate of ($1.17) by $0.14. The firm had revenue of $36.00 million during the quarter, compared to the consensus estimate of $29.38 million. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. As a group, equities analysts expect that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Morgan Stanley decreased their price objective on shares of Arcus Biosciences from $36.00 to $25.00 and set an "overweight" rating on the stock in a report on Tuesday, February 18th. Bank of America cut their price objective on shares of Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating for the company in a research report on Wednesday, February 19th. HC Wainwright raised Arcus Biosciences from a "neutral" rating to a "buy" rating and upped their target price for the company from $18.00 to $24.00 in a research report on Wednesday, February 26th. Finally, Barclays dropped their price target on Arcus Biosciences from $29.00 to $14.00 and set an "overweight" rating for the company in a report on Wednesday. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $28.38.

Arcus Biosciences Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.